The Nonconventional MHC Class II Molecule DM Governs Diabetes Susceptibility in NOD Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Morgan, Marc A J ^a   Muller, Pari S S ^a   Mould, Arne ^a   Newland, Stephen A ^b   Nichols, Jennifer ^b   Robertson, Elizabeth J ^a   Cooke, Anne ^b   Bikoff, Elizabeth K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA DM ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EMBRYONIC STEM CELL; FEMALE; GENETIC ENGINEERING; GERM LINE; INSULIN DEPENDENT DIABETES MELLITUS; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 1; EMBRYONIC STEM CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND;

EID: 84873917187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056738     Document Type: Article

References (45)

1. Todd JA, Bell JI, McDevitt HO, (1987) HLA-DQbeta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329: 599-604.
2. Serreze DV, Leiter EH, (2001) Genes and cellular requirements for autoimmune diabetes susceptibility in nonobese diabetic mice. Curr Dir Autoimmun 4: 31-67.
3. Todd JA, Wicker LS, (2001) Genetic protection from the inflammatory disease type diabetes in humans and animal models. Immunity 15: 387-395.
4. Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, et al. (2000) A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288: 505-511.
5. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, et al. (2000) Structural basis of peptide binding and presentation by the type 1 diabetes-associated MHC class II molecule of NOD mice. Immunity 12: 699-710.
6. Lee KH, Wucherpfennig KW, Wiley DC, (2001) Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nature Immunol 2: 501-507.
7. Busch R, Rinderknecht CH, Roh S, Lee AW, Harding JJ, et al. (2005) Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev 207: 242-260.
8. Hausmann DH, Yu B, Hausmann S, Wucherpfennig KW, (1999) pH-dependent peptide binding properties of the type 2 diabetes-associated I-A g7 molecule: rapid release of CLIP at an endosomal pH. J Exp Med 189: 1723-1734.
9. Fallang LE, Roh S, Holm A, Berseng T, Yoon T, et al. (2008) Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM. J Immunol 181: 5451-5461.
10. Hou T, Macmillan H, Chen Z, Keech CL, Jin X, (2011) An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: Implications for disease associations. J Immunol 187: 2442-2452.
11. Schulze MS, Wucherpfennig KW, (2012) The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Curr Opin Immunol 24: 105-111.
12. Mohan JF, Petzold SJ, Unanue ER, (2011) Register shifting of an insulin-peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208: 2375-2383.
13. Koonce CH, Bikoff EK, (2004) Dissecting MHC class II export, B cell maturation, and DM stability defects in invariant chain mutant mice. J Immunol 173: 3271-3280.
14. Mellanby RJ, Koonce CH, Monti A, Phillips JM, Cooke A, et al. (2006) Loss of invariant chain protects nonobese diabetic mice against type 1 diabetes. J Immunol 177: 7588-7598.
15. Nichols J, Jones K, Phillips JM, Newland SA, Roode M, et al. (2009) Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nature Med 15: 814-818.
16. Hanna J, Markoulaki S, Mitalipova M, Cheng AW, Cassady, et al, (2009) Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell 4: 1-12.
17. Hermel E, Yuan J, Monaco JJ, (1995) Characterization of polymorphism within the H2-M MHC class II loci. Immunogenetics 42: 136-142.
18. Peleraux A, Karlsson L, Chambers J, Peterson PA, (1996) Genomic organization of a mouse MHC class II region including the H2-M and Lmp2 loci. Immunogenetics 43: 204-214.
19. Bikoff EK, Wutz G, Kenty GA, Koonce CH, Robertson EJ, (2001) Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice. J Immunol 166: 5087-5098.
20. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, et al. (1996) H-2M mutant mice are defective in the peptide loading of class II molecules antigen presentation and T cell repertoire selection. Cell 84: 543-550.
21. Miyazaki T, Wolf P, Tourne S, Waltziner C, Dierich A, et al. (1996) Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84: 531-541.
22. Fung-Leung WP, Surh CD, Lijedahl M, Pang J, Leturcq D, et al. (1996) Antigen presentation and T cell development in H2-M-deficient mice. Science 271: 1278-1281.
23. Derbinski J, Kyewski B, (2010) How thymic antigen presenting cells sample the body's self-antigens. Curr Opin Immunol 22: 592-600.
24. Guerder S, Viret C, Luche H, Ardouin L, Malissen B, (2012) Differential processing of self-antigens by subsets of thymic stromal cells. Curr Opin Immunol 24: 99-104.
25. Klein L, Hinterberger M, Wirnberger G, Kyewski B, (2009) Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 9: 833-844.
26. Hinterberger M, Aichinger M, Prazerels da Costa O, Voehringer D, Hoffmann R, (2010) Autonomous role of medullary thymic epithelial cells in central CD4+ T cell tolerance. Nature Immunol 11: 512-519.
27. Koonce CH, Wutz G, Robertson EJ, Vogt AB, Kropshofer H, et al. (2003) DM loss in k haplotype mice reveals isotype-specific chaperone requirements. J Immunol 170: 3751-3761.
28. Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, et al. (1986) The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 231: 733-735.
29. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, et al. (2009) T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31: 643-653.
30. Stadinksi B, Kappler J, Eisenbarth GS, (2010) Molecular targeting of islet autoantigens. Immunity 32: 446-456.
31. Brode S, Raine T, Zaccone P, Cooke A, (2006) Cyclophosphamide-induced type 1-diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177: 6603-6612.
32. Suri A, Walters JJ, Gross ML, Unanue ER, (2005) Natural peptides selected by diabetogenic DQ8 and murine I- Ag7 molecules show common sequence specificity. J Clin Invest 115: 2268-2276.
33. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, et al. (2010) Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunol 11: 225-231.
34. Lieberman SM, DiLorenzo TP, (2003) A comprehensive guide to antibody and T cell responses in type 1 diabetes. Tissue Antigens 62: 359-377.
35. Lich JD, Jayne JA, Zhou D, Elliott JF, Blum JS, (2003) Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. J Immunol 171: 853-859.
36. Anders AK, Call MJ, Schulze MED, Fowler KD, Schubert DA, et al. (2011) HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nature Immunol 12: 54-61.
37. Jardetzky TS, Gorga JC, Busch R, Rothbard J, Strominger JL, et al. (1990) Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J 9: 1797-1803.
38. Gunther S, Schlundt A, Sticht J, Roske Y, Heinemann U, et al. (2010) Bidirectional binding of invariant chain peptides to an MHC class II molecule. Proc Natl Acad Sci USA 107: 22219-22224.
39. Tourne S, Miyazaki T, Wolf P, Ploegh H, Benoist C, et al. (1997) Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H-2M complexes. Proc Natl Acad Sci USA 94: 9255-9260.
40. Kovats S, Grubin CE, Eastman S, DeRoos P, Dongre A, et al. (1998) Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 187: 245-251.
41. Kenty G, Martin WD, van Kaer L, Bikoff EK, (1998) MHC class II expression in double mutant mice lacking invariant chain and DM functions. J Immunol. 160: 606-614.
42. Denzin LK, Fallas JL, Prendes M, Yi W, (2005) Right place, right time, right peptide: DO keeps DM focused. Immunol Rev 207: 279-292.
43. Karlsson L, (2005) DM and DO shape the repertoire of peptide-MHC -class II complexes. Curr Opin Immunol 17: 65-70.
44. Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant'Angelo DB, et al. (2010) Targeted regulation of self peptide presentation prevents type 1 diabetes in mice without disrupting general immunocompetence. J Clin Invest 120: 1324-1336.
45. Mellanby RJ, Philllips JM, Parish NM, Cooke A, (2008) Both central and peripheral tolerance mechanisms play roles in diabetes prevention in NOD-E transgenic mice. Autoimmunity 41: 383-394.